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Synthesis of a Regular 24-membered Cyclodepsipeptide by
Direct Amide Cyclization
Abstract
The synthesis of a 24-membered cyclic depsipeptide with an alternating sequence of phenyllactic acid
and α-aminoisobutyric acid (Aib) is described. The linear precursor was prepared via the
‘azirine/oxazolone method' using 2,2-dimethyl-3-amino-2H-azirines as building blocks for the
α,α-disubstituted α-amino acid Aib. The macrolactonization leading to the cyclodepsipeptide was
achieved by the ‘direct amide cyclization', i. e., by treatment of a solution of the linear precursor in
toluene with HCl gas.
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The synthesis of a 24-membered cyclic depsipeptide with an alternating sequence of phenyl-
lactic acid and α-aminoisobutyric acid (Aib) is described. The linear precursor was prepared via
the ‘azirine/oxazolone method’ using 2,2-dimethyl-3-amino-2H-azirines as building blocks for the
α ,α-disubstituted α-amino acid Aib. The macrolactonization leading to the cyclodepsipeptide was
achieved by the ‘direct amide cyclization’, i. e., by treatment of a solution of the linear precursor in
toluene with HCl gas.
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Introduction
Cyclic depsipeptides are macrocycles composed of
both amino acids and hydroxy acids, i. e., containing
lactam as well as lactone groups. As a result of the
well known biological activity of some representatives,
they are the subject of continous and current investiga-
tions. The majority of naturally occuring cyclic dep-
sipeptides have been isolated from marine or surface
cultures of the correspondingmicroorganisms [1]. The
current efforts to find new biologically active natural
examples are reflected in a large number of recent pa-
pers [2]. Two of the most well known cyclodepsipep-
tides are the antibiotics valinomycin [3] and enniatins
[4], which act as ionophores [5]. The special feature
of these 36- and 18-membered cyclodepsipeptides, re-
spectively, is their alternating sequence of α-amino
and α-hydroxy acids leading to macrocycles with al-
ternating lactam and lactone bonds. The pharmaceuti-
cal importance of, e. g., natural enniatins and synthetic
analogs stimulates the search for new natural exam-
ples and the attempts at synthesizing modified com-
pounds [6]. In practically all syntheses of cyclodep-
sipeptides, the cyclization is the crucial step. The ma-
jority of these ring closures have been carried out by
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the formation of either the amide bond (lactamization)
[7] or the ester bond (lactonization) [8].
A useful cyclization method for depsipeptides con-
taining α ,α-disubstituted α-amino acids, the so-called
‘direct amide cyclization’, has been developed in
our group [9 – 13]. The basic concept is shown in
Scheme 1: a solution or suspension of an amide of
type 1 in toluene is treated with dry HCl gas, whereby
the corresponding 1,3-oxazol-5(4H)-one derivative 2
is formed by ring closure and elimination of dimeth-
ylamine hydrochloride. In the absence of other nucle-
ophiles, the oxazolone 2 undergoes a ring enlargement
to yield the cyclic product 3 via an intramolecular at-
tack of the ω-hydroxy group onto the lactone func-
tionality.
Several cyclic depsipeptides which contain one hy-
droxy acid and several α ,α-disubstituted α-amino
acids have been prepared in our group by using this
cyclization method [9 – 12], e. g., the 12-membered 4
[9b] and the 16-membered 5 [12a]. In addition, syn-
theses of a 12-membered [9c] as well as some 18-
membered cyclodepsipeptides of type 6 [14, 15] with
an alternating sequence of α-hydroxy acids and α-
amino acids have been accomplished. Sterically de-
manding disubstituted amino acids have been incor-
porated into the linear precursors by the so-called
‘azirine/oxazolonemethod’ [16]. This particularly use-
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Scheme 1.
ful approach has also been applied successfully in the
syntheses of peptaibols [17], endothiopeptides [18],
and conformationally restricted cyclic peptides [19].
On the basis of these results it was of interest to as-
certain whether cyclodepsipeptides with a larger ring
size, and an alternating pattern of α-hydroxy acids and
α ,α-disubstituted α-amino acids can be synthesized
using the ‘direct amide cyclization’ for the macrolac-
tonization step. Our aimwas to prepare a 24-membered
cyclic depsipeptide containing four phenyllactic acid
and four Aib units. The incorporation of the amino acid
units into the linear precursor was again to be achieved
by using the ‘azirine/oxazolone method’.
Results and Discussion
Synthesis of the linear precursor
For our model compound, we selected an α-
hydroxy acid, which contained a chromophore to en-
sure that the final product can be detected by UV light.
Furthermore, the linear precursor was to bear a steri-
cally less congested alcohol function to facilitate the
ring closure. Therefore, (–)-(S)-phenyllactic acid (7)
was chosen. It was applied in its enantiopure form with
the aim of generating only a single diastereoisomer
of the linear precursor for the cyclization, and, hope-
fully, of the cyclodepsipeptide. As synthons for the in-
troduction of the α ,α-dimethyl glycine (Aib) units, 3-
(N,N-dimethylamino)-2H-azirine8a and 3-(N-methyl-
N-phenylamino)-2H-azirine 8b were used in the cou-
pling steps to give the corresponding amides.
The synthesis of the linear depsipeptide 15 is shown
in Scheme 2. The required O-benzyl-protected (S)-
phenyllactic acid (9) could not be synthesized by stan-
dard procedures, as it turned out that the configuration
at the α-carbon atom is labile under the basic condi-
tions of the benzylation of the OH group as well as the
basic ester hydrolysis. However, the enantiomerically
pure building block 9was obtained by the use of benzyl
trichloroacetimidate as the benzylating agent [20] and
subsequent acid-catalyzed hydrolysis of the methyl es-
ter. The enantiomeric purity of 9 has been proved after
coupling with 8b by means of HPLC chromatography
on a chiral stationary phase and comparison with the
racemic compound.
The diamide 10 was obtained in excellent yield by
coupling of 9with azirine 8b. Then, the terminal amide
bond was hydrolyzed by following the standard pro-
cedure of the ‘azirine/oxazolone method’ (3N HCl in
THF/H2O at r. t.) leading to the enantiomerically pure
building block 11 needed for the subsequent esterifi-
cation reaction. The required alcohol 12 was prepared
by coupling (S)-phenyllactic acid (7) with the azirine
8a. The N,N-dimethylazirine 8a, which affords the ter-
minal Me2N-amide 12, was chosen instead of the N-
methyl-N-phenyl azirine 8b, which leads to the N-
methyl-N-phenyl amide.Whereas the hydrolysis of the
Ph(Me)N amides is easier and usually occurs at r. t., it
had turned out in earlier experiments that the terminal
Me2N group is more suitable for the lactonization via
‘direct amide cylization’ [9 – 15].
The esterification of 11 and 12 was performed
in high yield using 1,1′-carbonyldiimidazole (CDI)
as the coupling reagent and sodium imidazolide as
the catalyst [9c]. Deprotection of the alcohol group
of the product 13 was achieved by hydrogenolysis
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Scheme 2.
(Pd catalysis). Subsequent twofold repetition of the
esterification and deprotection steps yielded the de-
sired precursor for the macrolactonization, viz. the
‘tetramer’ 15.
In order to obtain a ‘dimeric’ building block that al-
ready contains four alternating units and a carboxylic
acid function at the C terminus, attempts were made to
hydrolyze the terminal amide bond of 13 selectively.
Unfortunately, under the conditions applied, the es-
ter bond was also partially broken and, therefore, this
shorter approach to 15 was not successful.
Macrolactonization
The first cyclization attempt was carried out by ap-
plying the optimized conditions for the ring closure
to give 18-membered cyclodepsipeptides [15]. Treat-
ment of a solution of the precursor 15 in toluene at
100 ◦C with a stream of dry HCl gas for 4.5 min
led to a new product (TLC control). During work-up
and column chromatography, the latter decomposed,
so we assumed that only the oxazolone 16 was formed
during this relatively short reaction time, and that the
ring enlargement via nucleophilic addition of the ω-
hydroxy group onto the oxazolone to give the desired
24-membered ring did not take place.
Therefore, in a second experiment, the reaction mix-
ture was first treated with HCl gas as above and then
stirred under reflux for another 20 min to enable the
ring enlargement. Again, the same unstable intermedi-
ate was detected but could not be isolated. In the sub-
sequent lactonization attempt, the mixture was again
treated with HCl gas and then heated for 20 min under
reflux while the bubbling of a gentle HCl gas stream
through the solution was continued. In fact, a new
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Scheme 3.
product was formed (TLC), and the desired macrocy-
cle 17 could be isolated in 34% yield as a colorless
solid (Scheme 3).
These observations indicate a rapid formation of the
oxazolone intermediate 16 during the first HCl treat-
ment, but, in contrast to the synthesis of the corre-
sponding 18-membered cyclodepsipeptides [15], the
ring enlargement of the oxazolone via nucleophilic at-
tack of the ω-hydroxy group at the oxazolone C=O
group does not take place. Entropic reasons may be re-
sponsible for this difference in reactivity, as the chance
for the two reaction centers to come together is smaller
with increasing length of the chain. Even prolonged
heating under reflux does not lead to the 24-membered
ring. The ring closure/ring expansion only proceeds if
HCl gas is bubbled through the reaction mixture dur-
ing heating. Apparently, the intermediate oxazolone 16
has to be activated by protonation, which can be en-
sured by maintaining a high HCl concentration in the
reaction mixture.
The yield of 34% for the cyclodepsipeptide 17 is
comparable with that of other cyclization methods for
macrolactones of this ring size. Unfortunately, the es-
ter bonds of the cyclization precursor 15 are not com-
pletely stable under the conditions of the ‘direct amide
cylization’, as has been shown by control experiments
in methanolic solution [15]. It is most likely that cleav-
age of ester groups in the linear depsipeptide under
these acidic conditions also occurs via the formation of
1,3-oxazol-5(4H)-ones as intermediates, which, with
traces of water or during workup, are transformed into
the corresponding acids.
Fig. 1. ORTEP plot [21] of the molecular structure of 17
(50% probability ellipsoids, arbitrary numbering of atoms).
Crystallization of a sample of 17 from a mixture
of xylene, CCl4 and acetone by slow evaporation of
the solvent gave crystals suitable for an X-ray crystal
structure determination. The molecular structure of 17
is shown in Fig. 1. It shows the cyclic depsipeptide
with an epimerized configuration of one of the four
stereogenic centers, i. e., the molecule has the 3R,9S,
15S,21S configuration.
The available crystal was not of optimal quality and
weakly diffracting, thus the refinement results are of
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only moderate precision. However, the overall struc-
ture is unambiguous. The space group suggests that
the compound in the crystal is enantiomerically pure,
but the absolute configuration of the molecule has not
been determined. The compound has either the R,S,
S,S or the S,R,R,R configuration. Based on the expec-
tation from the chemical synthesis that the compound
should have the R,S,S,S configuration, this assumption
was used to define the model used in the refinement as
3R,9S,15S,21S. Despite the obvious asymmetry aris-
ing from the chiral centers, the molecule is pseudo-
centrosymmetric with 97% of the atoms closely fitting
the centrosymmetric relationship. The asymmetric unit
also includes two molecules of p-xylene. The macro-
cyclic molecule contains two intramolecular hydro-
gen bonds (N(11)–H· · ·O(4) and N(23)–H· · ·O(16)),
which link two diametrically opposite amide N–H
groups to the next amide O atom around the ring, af-
ter an intervening ester group. These interactions form
loops with a graph set motif [22] of S(10), i. e., β -
turns. The other amide N–H groups form intermolec-
ular hydrogen bonds to diametrically opposed ester
carbonyl O atoms in adjacent molecules, one inter-
action being with the next molecule in the [100] di-
rection [N(5)–H· · ·O(13′)], and the other interaction
with the next molecule in the [1¯00] direction [N(17)–
H· · ·O(1′′)]. Each of the intermolecular interactions
links the molecules into extended chains which run
parallel to the crystallographic x axis and have a graph
set motif of C(11). As these interactions run antiparal-
lel to one another and link the same pairs of molecules,
the two independent intermolecular interactions com-
bined give rise to the formation of a ring between
the molecules which has a binary graph set motif of
R2,2(14).
In accord with the observations for the correspond-
ing 18-membered cyclodepsipeptides [15], epimeriza-
tion also occurred in the present case at one of the
stereogenic centers, and only one diastereoisomer was
obtained. The stereogenic center in α-position to the
oxazolone 16 (Scheme 3), i. e., the first stereogenic
center counting from the former amide terminus, is
configurationally unstable under the applied conditions
of the ‘direct amide cyclization’, as could be shown
by control experiments in the case of the lower ho-
mologs of type 14 [15] (see also ref. [23]). Therefore,
it is reasonable to assume that the epimerization also
took place at this center in the case of 15. It has not
been clarified why only the product with one inverted
center was obtained, as a mixture of diastereoisomers
might be anticipated. But in the case of a similar 18-
membered depsipeptide, a different lactonization using
the Corey-Nicolaoumethod [24] showed that the R,S,S
epimer undergoes the cyclization much easier than the
S,S,S isomer [15]. The inverted configuration may pro-
mote a different conformation that is more suitable for
the attack of the ω-hydroxy group onto the oxazolone
moiety. A comparable observation was reported re-
cently [25]: The base-catalyzed cyclooligomerization
of (3S,6S)-3-isopropyl-6-methylmorpholine-2,5-dione
led to cyclic di-, tri-, and tetramers, i. e., cyclic dep-
sipeptides with alternating lactic acid and valine units,
with extensive epimerization. For example, one of the
isomeric 24-membered rings was obtained in crys-
talline form, and the X-ray crystal structure determi-
nation established the (R,R,R,S,R,R,R,S)-configuration
with only two valine residues showing the original (S)-
configuration.
Conclusions
The 24-membered cylic depsipeptide 17 with an al-
ternating sequence of an α-hydroxy acid and an α ,α-
disubstituted α-amino acid, i. e., phenyllactic acid and
aminoisobutyric acid (Aib), has been synthesized. The
preparation of the linear depsipeptide 15 as the precur-
sor of the cyclization has been accomplished by the use
of the efficient ‘azirine/oxazolone method’ to incorpo-
rate the Aib units, followed by ester formation of the
segments. The macrolactonization step was achieved
via the ‘direct amide cyclization’ and yielded the de-
sired product 17 in a yield of 34%. The structure of
the cyclic depsipeptide has been determined by X-ray
analysis, which has proved that the cyclization occurs
with inversion of the configuration of the α-hydroxy
acid next to the amide terminus of 15. It has thus been
demonstrated that this methodology is also useful for
the preparation of cyclodepsipeptideswith larger rings,
i. e., higher homologues of the enniatins. However, the
cyclization step has to be improved to avoid epimeriza-
tion.
Experimental Section
General remarks
The azirines 8a and 8b, i. e., 2,2,N,N-tetramethyl-2H-
azirin-3-amine and 2,2,N-trimethyl-N-phenyl-2H-azirin-3-
amine, were prepared according to standard procedures (see
ref. [16] and refs. cited therein). All other products used
were commercially available. Solvents were purified by stan-
dard procedures. Thin-layer chromatography (TLC): Merck
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TLC aluminium sheets, silica gel 60 F254. Flash chromatog-
raphy (FCC): Uetikon-Chemie ‘Chromatographiegel’ C-560.
Melting points: Bu¨chi 540 apparatus, uncorrected. IR Spec-
tra: Perkin-Elmer Spectrum one spectrometer; in CHCl3, ab-
sorption bands in cm−1. 1H NMR (300 and 600 MHz) and
13C NMR (75.5 and 151 MHz) spectra: Bruker ARX-300
and Bruker DRX-600 instrument, respectively, in CDCl3 at
300 K, TMS as internal standard, δ in ppm, coupling con-
stants J in Hz, 13C signal multiplicities from DEPT spec-
tra. Mass spectrometry (MS): Finnigan MAT 90 for electron-
impact ionization (EI), Finnigan SSQ-700 for chemical ion-
ization (CI, with NH3) and electrospray ionization (ESI, in
MeOH + NaI).
General procedure 1 (GP1). Reaction of azirines 8a and 8b
with acids 7 and 9
To a stirred solution of the corresponding acid in dry
MeCN was added a solution of the azirine in dry MeCN. The
mixture was stirred at r. t. for 16 h, the solvent was evapo-
rated, and the residue was purified by FCC.
General procedure 2 (GP2). Esterification of acid 11 with
the corresponding alcohols and subsequent hydrogenolysis
of the benzyl ether
A solution of 11 and 1.0 equiv. of 1,1′-carbonyldiimid-
azole (CDI) in dry THF was stirred for 2 h under N2. The
corresponding alcohol was then added, followed by 10 drops
of a sodium imidazolide suspension (freshly prepared by the
reaction of 45 mg of a 60% dispersion (w/w) of NaH in min-
eral oil and 73 mg of imidazole in 3 mL of dry THF). After
completion of the reaction (monitored by TLC, 2 – 16 h), the
solvent was evaporated and the mixture purified by FCC. The
product was then dissolved in THF/iPrOH 1 : 1, a catalytic
amount of Pd on charcoal was added, and the suspension
was stirred under a hydrogen atmosphere until completion of
the reaction (TLCmonitoring). The mixture was then filtered
over Celite, the solvent evaporated, and the residue purified
by FCC.
(–)-(2S)-2-Benzyloxy-3-phenylpropanoic acid (9)
To a solution of (–)-(S)-phenyllactic acid (7, 11.1 mmol,
1.84 g) in MeOH (20 mL) were added 5 drops of conc. H2
SO4, and the mixture was heated for 1 h under reflux. Then,
ethyl acetate (30 mL) was added, the mixture extracted once
with 20 mL of a saturated aqueous NaHCO3 solution, dried
with MgSO4, and evaporated. Within 2 h, benzyl 2,2,2-tri-
chloroacetimidate (2.80 g, 11.1 mmol, 2.07 mL) was added
to a solution of the obtained methyl ester followed by 5 drops
of CF3SO3H in CH2Cl2/hexane 1 : 1 (100 mL) in analogy to
ref. [20], and the mixture was stirred for 10 h. After evap-
oration of the solvent, the product was separated from re-
maining starting material by FCC (SiO2, hexane/Et2O 1 : 1),
dissolved in dioxane (70 mL). Aqueous 2M HCl (70 mL)
was added, and the mixture was stirred at 70 ◦C for 6 h.
Then, brine (100 mL) was added, most of the organic sol-
vent evaporated, and the residue extracted with ethyl acetate
(3×80 mL). The combined organic fractions were extracted
with saturated aqueous NaHCO3 solution (6× 50 mL), the
combined aqueous fractions were adjusted to pH = 1 by ad-
dition of HCl and extracted with ethyl acetate (3× 80 mL).
Evaporation of the solvent after drying with MgSO4 gave
9 (1.45 g, 5.66 mmol, 51%) in pure form. Analytical data
including the [α]D value were in accord with the data in
ref. [26].
(–)-(S)-2-Benzyloxy-N-[1-methyl-1-(N-methyl-N-
phenylcarbamoyl)ethyl]-3-phenylpropanamide (10)
According to GP 1, 9 (1.0 g, 3.9 mmol) in MeCN (20 mL),
8b (680 mg, 3.9 mmol) in MeCN (5 mL), 14 h, FCC (SiO2,
hexane/Et2O 1 : 1): 1.49 g (89%) of 10. White powder, m. p.
92 ◦C. – IR: ν = 3407m, 3353w, 3031m, 3020s, 3013m,
2930w, 2876w, 2460w, 1952w, 1674s, 1636s, 1594m, 1496s,
1455m, 1388m, 1365m, 1245m, 1205m, 1117m, 1092s,
1030w, 912w. – 1H NMR: δ = 1.36 (s, 6H, 2 Me), 2.89 (dd,
J = 7.7, 14.1, 1H of PhCH2), 3.14 (dd, J = 3.6, 14.1, 1H
of PhCH2), 3.25 (s, 3H, MeN), 3.86 (dd, J = 3.6, 7.7, 1H,
CHO), 4.29 (s, 2H, PhCH2O), 7.10 – 7.40 (m, 11H, NH + 2
Ph). – 13C NMR: δ = 25.7, 26.3 (2q, 2 Me), 38.4 (t, PhC
H2), 41.4 (q, MeN), 57.8 (s, Me2C), 72.8 (t, PhCH2O), 81.1
(d, CHO), 126.3, 127.8, 128.1, 128.3, 129.2, 129.7 (6d, 10
arom. CH), 137.1, 137.4 (2s, 2 arom. C), 170.3, 173.0 (2s, 2
C=O). – MS (EI): m/z (%) = 324 (21) [M–Ph(Me)N]+, 296
(36) [M–Ph(Me)NCO]+, 107 (54) [C7H7O]+, 91 (100) [C7
H7]+. – [α]25D : −51.4 (c = 1.1, CHCl3). The enantiomeric
purity was proved by analytical HPLC on a Chiralcel OD-H
column (hexane/i-PrOH 13 : 1).
(–)-(S)-2-(2-Benzyloxy-3-phenylpropanoylamino)-2-
methylpropanoic acid (11)
To a solution of amide 10 (1.29 g, 3.0 mmol) in THF
(15 mL) was added 6N HCl (15 mL), and the mixture was
stirred for 6 h at r. t. Subsequent addition of 2N HCl (15 mL),
extraction with Et2O (3×20 mL), drying of the combined or-
ganic fractions with MgSO4, and evaporation of the solvent
gave 11 (1.00 g, 98%). White powder, m. p. 126 – 127 ◦C. –
IR: ν = 3413m, 3066m, 3031s, 3021s, 2929m, 2876m,
1951w, 1718s, 1675s, 1517s, 1497m, 1456s, 1300m, 1228m,
1171m, 1090s, 911w. – 1H NMR: δ = 1.45, 1.47 (2s, 2×3H,
2 Me), 2.94 (dd, J = 7.6, 14.1, 1H of PhCH2), 3.18 (dd, J =
3.6, 14.1, 1H of PhCH2), 4.10 (dd, J = 3.6, 7.6, 1H, CHO),
4.47 (s, 2H, PhCH2O), 6.96 (s, 1H, NH), 7.18 – 7.34 (m,
10H, 2 Ph), 8.20 (br. s, 1H, CO2H). – 13C NMR: δ = 24.2,
24.8 (2q, 2 Me), 38.8 (t, PhCH2), 56.3 (s, Me2C), 73.2 (t,
PhCH2O), 80.7 (d, CHO), 126.6, 127.9, 128.1, 128.1, 128.5,
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129.7 (6d, 10 arom. CH), 136.8 (s, 2 arom. C), 172.7, 177.0
(2s, 2 C=O). – MS (CI): m/z (%) = 359 (7) [M + NH4]+, 342
(100) [M + H]+. – [α]25D : −58.7 (c = 1.3, CHCl3).
(–)-(S)-N-(1-Dimethylcarbamoyl-1-methylethyl)-2-hydroxy-
3-phenyl-propanamide (12)
According to GP 1, 7 (2.0 g, 12.1 mmol) in MeCN
(50 mL), 8a (1.49 g, 13.3 mmol) in MeCN (15 mL), 14 h,
FCC (SiO2, CH2Cl2/MeOH 30 : 1): 3.06 g (91%) of 12.
White powder, m. p. 156 – 158 ◦C. – IR: ν = 3603w, 3406m,
3346m, 3021s, 3012m, 2942w, 2460w, 1671s, 1629s, 1508s,
1454w, 1395m, 1242m, 1120m, 1086m. – 1H NMR: δ =
1.55, 1.56 (2s, 2× 3H, 2 Me), 2.89 (dd, J = 8.0, 13.9, 1H
of PhCH2), 2.98 (s, 6H, Me2N), 3.18 (dd, J = 4.0, 13.9, 1H
of PhCH2), 4.27 (dd, J = 4.0, 8.0, 1H, CHO), 7.20 – 7.32 (m,
5H, Ph), 7.41 (s, 1H, NH). – 13C NMR: δ = 24.8, 24.9 (2q,
2 Me), 38.0 (q, Me2N), 40.6 (t, PhCH2), 56.5 (s, Me2C), 72.6
(d, CHO), 126.8, 128.5, 129.6 (3d, 5 arom. CH), 136.9 (s,
arom. C), 171.1, 172.6 (2s, 2 C=O). – MS (CI): m/z (%) =
279 (100) [M + H]+, 234 (23) [M–Me2N]+. – [α]25D : −58.4
(c = 1.0, CHCl3).
(–)-(S)-1-[(1-Dimethylcarbamoyl-1-methylethyl)carb-
amoyl]-2-phenylethyl 2-((S)-2-hydroxy-3-phenylpropanoyl-
amino)-2-methylpropanoate (13)
According to GP 2, 11 (1.23 g, 3.60 mmol), CDI
(583 mg, 3.60 mmol), 12 (1.0 g, 3.60 mmol), THF (40 mL),
2 h, FCC (SiO2, CH2Cl2/MeOH 50 : 1): 1.56 g (85%) of
13. White powder, m. p. 96 – 97 ◦C. – IR: ν = 3672w,
3601w, 3413m, 3303m, 3021m, 3010m, 2462w, 1950w,
1745s, 1662s, 1624s, 1532s, 1498m, 1455m, 1396m, 1366m,
1286m, 1247m, 1147s, 1089m, 1061m, 1031w, 998w, 889w,
862w. – 1H NMR: δ = 1.26, 1.33, 1.48, 1.53 (4s, 4× 3H,
4 Me), 2.70 – 3.60 (m, 10H, Me2N + 2 PhCH2), 4.10 – 4.26
(m, 2H, CHOH + OH), 5.29 – 5.41 (m, 1H, CHOCO), 7.10 –
7.36 (m, 12H, 2 Ph + 2 NH). – 13C NMR: δ = 24.4, 24.9,
25.4, 26.1 (4q, 4 Me), 37.6, 40.1 (2t, 2 PhCH2), 37.9 (q,
Me2N), 55.4, 56.5 (2s, 2 Me2C), 72.3, 74.4 (2d, 2 CHO),
126.6, 126.7, 128.2, 128.2, 129.5, 129.6 (6d, 10 arom. CH),
136.2, 137.0 (2s, 2 arom. C), 168.1, 172.9, 173.0, 173.9 (4s, 4
C=O). – MS (ESI):m/z (%) = 556 (14) [M +MeOH + Na]+,
534 (100) [M + Na]+. – Anal. for C28H37N3O6 (511.61):
calcd. C 65.73, H 7.29, N 8.21; found C 65.24, H 7.65,
N 7.96. – [α]25D : −60.3 (c = 1.0, CHCl3).
(–)-(S)-1-[(1-Dimethylcarbamoyl-1-methylethyl)carb-
amoyl]-2-phenylethyl 2-{(S)-2-[2-((S)-2-hydroxy-3-phen-yl
propanoylamino)-2-methylpropanoyloxy]-3-phenyl-
propanoylamino}-2-methylpropanoate (14)
According to GP 2, 11 (1.23 g, 3.60 mmol), CDI (583 mg,
3.61 mmol), 13 (1.84 g, 3.60 mmol), THF (40 mL), 8 h,
FCC (SiO2, CH2Cl2/MeOH 50 : 1): 2.22 g (83%) of 14.
White powder, m. p. 101 – 103 ◦C. – IR: ν = 3671w, 3601w,
3410m, 3283s, 3066m, 3010m, 2939m, 2463w, 2338w,
1950w, 1878w, 1744s, 1650s, 1543s, 1497m, 1471m, 1455,
1440, 1388, 1366, 1269s, 1198m, 1146s, 1089m, 1063m,
1031m, 1001w, 960w, 941w, 912w, 888w, 864w, 844w. –
1H NMR: δ = 1.24, 1.26, 1.38, 1.44, 1.56, 1.60 (6s, 6×3H,
6 Me), 2.98 – 3.45 (m, 12H, Me2N + 3×PhCH2), 3.50 (br.
s, 1H, OH), 4.28 – 4.35 (m, 1H, CHOH), 5.30 – 5.40 (m, 2H,
2 CHOCO), 7.19 – 7.41 (m, 16H, 3 Ph + 1 NH), 7.82, 8.10
(2s, 2×1H, 2 NH). – 13C NMR: δ = 24.2, 24.3, 24.9, 25.3,
25.8, 26.2 (6q, 6 Me), 37.5, 38.0, 40.2 (3t, 3 PhCH2), 37.8
(q, Me2N), 55.5, 56.1, 56.4 (3s, 3 Me2C), 72.3, 74.6, 74.9
(3d, 3 CHO), 126.6, 126.8, 126.9, 128.2, 128.2, 128.4, 129.4,
129.6, 129.7 (9d, 15 arom. CH), 136.0, 136.5, 136.7 (3s,
3 arom. C), 168.4, 169.9, 172.8, 172.86, 173.3, 173.6 (6s,
6 C=O). – MS (ESI): m/z (%) = 767 (100) [M + Na]+. –
Anal. for C41H52N4O9 (744.89): calcd. C 66.11, H 7.04,
N 7.52; found C 65.53, H 7.09, N 7.37. – [α]25D : −60.4 (c =
1.4, CHCl3).
(–)-(S)-1-[(1-{1-[(1-Dimethylcarbamoyl-1-methylethyl)
carbamoyl]-(S)-2-phenylethoxycarbonyl}-1-methylethyl)
carbamoyl]-2-phenylethyl 2-{(S)-2-[2-((S)-2-hydroxy-
3-phenylpropanoylamino)-2-methylpropanoyloxy]-3-
phenylpropanoylamino}-2-methylpropanoate (15)
According to GP 2, 11 (1.23 g, 3.60 mmol), CDI (583 mg,
3.61 mmol), 14 (2.68 g, 3.60 mmol), THF (40 mL), 16 h,
FCC (SiO2, CH2Cl2/MeOH 50 : 1): 2.81 g (80%) of 15.
White powder, m. p. 88 – 90 ◦C. – IR: ν = 3601w, 3413m,
3282s, 3066m, 3021m, 3009m, 2930m, 1951w, 1744s,
1651s, 1547s, 1497m, 1471m, 1455m, 1388m, 1366m,
1269m, 1147s, 1083m, 1063m, 1031m, 1002w, 939w, 889w,
864w. – 1H NMR: δ = 1.23, 1.41, 1.45, 1.52, 1.59 (5s,
8× 3H, 8 Me), 2.90 – 3.35 (m, 14H, Me2N + 4 PhCH2),
4.21 – 4.29 (m, 1H, CHOH), 5.02 – 5.09, 5.21 – 5.31 (2m,
1H + 2H, 3 CHOCO), 7.16 – 7.39 (m, 21H, 4 Ph + 1 NH),
7.80, 8.04, 8.11 (3s, 3× 1H, 3 NH). – 13C NMR: δ =
24.3, 25.2, 25.4, 25.9, 26.3 (5q, 8 Me), 37.6, 37.8, 38.0,
40.2 (4t, 4 PhCH2), 37.9 (q, Me2N), 55.6, 56.1, 56.6 (3s,
4 Me2C), 72.4, 74.6, 75.1, 75.6 (4d, 4 CHO), 126.7, 126.86,
126.91, 127.0, 128.3, 128.3, 128.5, 129.6, 129.8, 129.9 (10d,
20 arom. CH), 136.1, 136.6, 136.7, 137.0 (4s, 4 arom. C),
168.6, 170.1, 170.5, 172.9, 173.1, 173.4, 173.5, 173.8 (8s,
8 C=O). – MS (ESI): m/z (%) = 1000 (100) [M + Na]+. –
Anal. for C54H67N5O12 (978.14): calcd. C 66.31, H 6.90,
N 7.16; found C 65.55, H 6.88, N 7.00. – [α]25D : −58.7 (c =
1.0, CHCl3).
(–)-(6R,12S,18S,24S)-6,12,18,24-Tetrabenzyl-3,3,9,9,
15,15,21,21-octamethyl-1,7,13,19-tetraoxa-4,10,16,22-
tetraazacyclotetracosan-2,5,8,11,14,17,20,23-octaone (17)
Dry HCl gas was bubbled through a solution of 15
(300 mg, 0.31 mmol) in toluene (30 mL) at 100 ◦C for
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4.5 min. The mixture was then heated under reflux for
20 min while a gentle stream of dry HCl gas was bub-
bled through the solution. The mixture was allowed to cool
to r. t. while bubbling N2 through it. Evaporation of the
solvent and column chromatography (SiO2, CH2Cl2/MeOH
50 : 1) gave 17 (96 mg, 34%). White powder, m. p. 133 –
134 ◦C. – IR: ν = 3272m, 3066w, 3031w, 3009w, 2930w,
1745s, 1645s, 1553m, 1455w, 1388m, 1309w, 1269m, 1145s,
1064m, 909w. – 1H NMR: δ = 1.18 – 1.68 (m, 24H, 8 Me),
2.86 – 3.43 (m, 8H, 4 PhCH2), 4.95 – 5.49 (m, 4H, 4 CHO),
6.90 – 7.47 (m, 20H, 4 Ph), 7.89 – 8.40 (m, 4H, 4 NH). –
13C NMR (broad signals): δ = 24.8 (q, 8 Me), 37.6 (t,
4 CH2), 56.0 (s, 4 Me2C), 75.4 (d, 4 CHO), 126.8, 128.2,
129.7 (3d, 20 arom. CH), 136.8 (s, 4 arom. C), 170.0, 173.6
(2s, 8 C=O). – MS (ESI): m/z (%) = 955 (100) [M + Na]+. –
Anal. for C52H60N4O12·H2O (933.04·H2O): calcd. C 65.67,
H 6.57, N 5.89; found C 65.75, H 6.89, N 5.73. – [α]25D :
−41.0 ( c = 0.8, CHCl3).
X-Ray crystal-structure determination of 17
All measurements were performed on a Nonius Kap-
paCCD area detector diffractometer [27] using graphite-
monochromatized MoKα radiation (λ = 0.71073 A˚) and an
Oxford Cryosystems Cryostream 700 cooler. The data col-
lection and refinement parameters are given below [28] and
a view of the molecule is shown in Fig. 1. Data reduction
was performed with HKL DENZO and SCALEPACK [29].
The intensities were corrected for Lorentz and polarization
effects, but not for absorption. Equivalent reflections were
merged. The structure was solved by Direct Methods using
SIR92 [30], which revealed the positions of all non-H atoms.
The non-H atoms were refined anisotropically. All H atoms
were placed in geometrically calculated positions and refined
by using a riding model where each H atom was assigned a
fixed isotropic displacement parameter with a value equal to
1.2Ueq of its parent C atom (1.5Ueq for the methyl groups).
The refinement of the structure was carried out on F2 using
full-matrix least-squares procedures, which minimized the
function Σw(Fo2−Fc2)2. A correction for secondary extinc-
tion was applied. Neutral atom scattering factors for non-H
atoms were taken from ref. [31], and the scattering factors for
H atoms were taken from ref. [32]. Anomalous dispersion ef-
fects were included in Fc [33]; the values for f ′ and f ” were
those of ref. [34]. The values of the mass attenuation coeffi-
cients are those of ref. [35]. All calculations were performed
using the SHELXL-97 [36] program.
Crystal data for 17: C52H60N4O12 ·2C8H10,M = 1145.39,
crystallized from xylene/CCl4/acetone, colorless, prism,
crystal dimensions: 0.10×0.20×0.22 mm3, triclinic, space
group P1, Z = 1, reflections for cell determination: 5495,
2θ range for cell determination: 4 – 50◦, a = 10.0596(4),
b = 11.1402(5), c = 14.9075(7) A˚, α = 76.869(2)◦ , β =
87.668(2)◦ , γ = 76.776(2)◦ ,V = 1583.7(1) A˚3, T = 160(1) K,
Dx = 1.201 g cm−3, µ(MoKα ) = 0.0820 mm−1, scan type
ω , 2θmax = 50◦, total reflections measured: 23521, sym-
metry independent reflections: 5539, reflections with I ≥
2σ(I): 3042, reflections used in refinement: 5539, param-
eters refined: 770, restraints: 3, R(F) [I ≥ 2σ(I) reflec-
tions] = 0.0638, wR(F2) (all data) = 0.1714 (w = [σ2(Fo2) +
(0.0568P)2]−1, where P = (Fo2 +2Fc2)/3), goodness of
fit: 1.037, final ∆max/σ = 0.001, ∆ρ (max; min) = 0.26;
−0.30 e A˚−3, secondary extinction coefficient = 0.015(3).
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